Drug Profile
Acitretin - AbbVie
Alternative Names: Acitretine; Etretin; Neotigason; RO 101670; SoriataneLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Roche
- Developer AbbVie; Aralez Pharmaceuticals Inc.; Innovaderm Research; Old API Wind-down Ltd; Roche; Stiefel Laboratories; University of Medicine & Dentistry of New Jersey
- Class Antipsoriatics; Keratolytics; Retinoids
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Psoriasis
- Discontinued Cancer; Dermatitis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
- 10 Jul 2017 Discontinued - Phase-II for Psoriasis (Adjunctive treatment) in USA (PO), because not listed on Allergan pipeline, July 2017